CAS BioFinder Discovery Platform™
Advance your drug discovery program with integrated chemistry and biological data and advanced prediction capabilities.
Confidently Advance Drug Discovery
Working through the literature to find disease targets, plan structure-activity relationship studies, and assess the potential for off-target interactions takes time and risks missing key information. The CAS BioFinder Discovery Platform brings together the data and solutions needed across drug discovery workflows, including discovery biology and medicinal chemistry.
Enhanced Biological Data for Your Drug Development Success
Designed to support the needs of biology-based inquiry and sequence searches, the CAS BioFinder Discovery Platform pulls from new data types, authorities, and connections in the CAS Content Collection™.
With enhanced bioactivity data on ligands, their interactions with proteins and diseases, related biomarkers, and pathways, you have better access than ever to the full range of data needed for drug development.
With CAS BioFinder, you can explore connections between ligands, targets, and diseases and run AI-enhanced predictive bioactivity models with data derived from existing literature. This ensures you always have the most relevant results.
In addition to existing and predicted bioactivity, ligand, sequence, disease, and biomarker data, CAS BioFinder also integrates 3D protein models and details to save time and advance your drug discovery program.
Answer Your Critical Drug Discovery Questions
What Scaffolds and Molecules are Associated with Your Disease of Interest?
Investigate associations between diseases, targets, pathways, and ligands, with references and experimental conditions to support the evidence.
What Biomarkers are Relevant to Your Disease of Interest?
Discover evidence-based connections between biomarkers and diseases and research their involvement in biological pathways.
Which Molecules will make the Best Leads?
Focus on molecules with specific drug-like properties or that have already been approved as drugs, screen for potential safety issues, and identify known and potential metabolites.
How will Your Molecules Interact with Proteins and Impact Biological Processes?
Predict targets and bioactivity values for known and novel molecules and explore pathways and cellular processes affected by the molecule-protein interaction.
What Molecules are Known or Likely to be Active Against Your Target of Interest?
Find normalized bioactivity data and similar scaffolds to investigate and use AI-enhanced tools to predict the bioactivity of ligands against a specific target.
CAS Custom Data Science and Knowledge Management Consulting Services
Partner directly with expert scientists at CAS to design custom solutions by leveraging our content, technology, and expertise in new ways to drive innovation and solve unique R&D and business challenges.
Intertwined Solutions for Successful Digital Transformation
Maximizing your data involves the strategic implementation of strong AI models and advanced analytics. This requires a robust data foundation set through solid knowledge management strategies.
With CAS Custom ServicesSM, you can master every aspect of your data framework to secure reliable, evidence-based insights that set your company up for success.
About Drug Discovery Innovation Programme 2025
The Drug Discovery Innovation Programme, organized by World BI, is an exclusive, invitation-only event designed to connect leading scientists, researchers, and industry pioneers in a dynamic and collaborative environment.
Join us in person to gain insights from top experts in drug discovery and development, exploring the latest breakthroughs, emerging technologies, and innovative approaches shaping the future of the industry. With a forward-thinking agenda covering small molecule discovery, biologics, AI-driven translational medicine, and regulatory insights, DDIP 2025 will feature tailored sessions led by global leaders.
Bringing together visionaries from Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals, Amgen, Novo Nordisk, AbbVie, GSK, Exelixis, Insilico Medicine, and many more, this event is your opportunity to expand your knowledge, network with key stakeholders, and accelerate your drug development journey.